Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
MRI lesions: a surrogate for relapses in multiple sclerosis?
Brain iron deposition in white matter hyperintensities: a 3-T MRI study.
Acute toxic neuropathy mimicking guillain barre syndrome.
Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction.
[Differential diagnosis of optic neuritis (review].
Predictors and impact of the working alliance in the neuropsychological rehabilitation of patients with multiple sclerosis.
Pathologic role of glial nitric oxide in adult and pediatric neuroinflammatory diseases.
Two functional promoter polymorphisms of neuregulin 1 gene are associated with progressive forms of multiple sclerosis.
Optimization of Magnetization-Prepared 3-Dimensional Fluid Attenuated Inversion Recovery Imaging for Lesion Detection at 7 T.
Teva to present further results of twenty-year open-label extension study of glatiramer acetate 20 mg daily for relapsing-remitting multiple sclerosis
Re: Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med
Labeling mesenchymal cells with DMSA-coated gold and iron oxide nanoparticles: assessment of biocompatibility and potential applications.
Clustering of autoimmune diseases in patients with rosacea.
Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis.
Evaluation of Multi-Atlas Label Fusion for In Vivo MRI Orbital Segmentation.
Measuring myeloperoxidase activity in biological samples.
Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects.
Reliability of the Swedish version of the Exercise Self-Efficacy Scale (S-ESES): a test-retest study in adults with neurological disease.
Regenerative Medicines for Remyelination: From Aspiration to Reality.
Pediatric multiple sclerosis.
Reply to Letter to the Editor re: Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: Correlation with cumulative dose of a macrocy
Targeting Central Nervous System B Cells in Progression of Multiple Sclerosis: Is Intrathecal Anti-CD20 a Therapeutic Option?
[Clinico-radiological profile of acute disseminated encephalomyelitis in the childhood population. A retrospective analysis of a series of 20 patients in a tertiary hospital].
Orthopaedic Management of Spasticity.
[Acute disseminated encephalomyelitis is an important differential diagnosis in the acutely affected child].
Pages
« first
‹ previous
…
523
524
525
526
527
528
529
530
531
…
next ›
last »